TY - JOUR
T1 - Human 6-Sulfo LacNAc-Expressing Dendritic Cells Are Principal Producers of Early Interleukin-12 and Are Controlled by Erythrocytes
AU - Schäkel, Knut
AU - von Kietzell, Matthias
AU - Hänsel, Anja
AU - Ebling, Annette
AU - Schulze, Livia
AU - Haase, Michael
AU - Semmler, Christian
AU - Sarfati, Marika
AU - Barclay, A. Neil
AU - Randolph, Gwendalyn J.
AU - Meurer, Michael
AU - Rieber, E. Peter
N1 - Funding Information:
We thank Colleen Schmitz and Michael Bachmann for critical reading of the manuscript. This work was supported by the Medical Faculty, Technische Universität Dresden. The authors declare that they have no competing financial interest.
PY - 2006/6
Y1 - 2006/6
N2 - Early and high-level production of IL-12 is crucial for effective immune responses against pathogens. Up until now, the cells providing this initial IL-12 have remained elusive. Here we show that a subset of human blood dendritic cells (DC) is the principal and primary source of IL-12p70 when blood leukocytes are stimulated with the TLR4-ligand LPS or with CD40-ligand. These so-called slanDC are characterized by the 6-sulfo LacNAc modification of PSGL-1, which is identified by the mAb M-DC8. The IL-12 response of slanDC requires a few hours of in vitro maturation, which is completely blocked in the presence of erythrocytes. This inhibition of maturation depends on the expression of CD47 on erythrocytes and of its ligand SIRPα on DC. While strictly controlled in the blood by erythrocytes, the high IL-12- and TNF-α-producing capacity of slanDC in tissues may be critical in fighting off pathogens; if uncontrolled, it may lead to adverse inflammatory reactions.
AB - Early and high-level production of IL-12 is crucial for effective immune responses against pathogens. Up until now, the cells providing this initial IL-12 have remained elusive. Here we show that a subset of human blood dendritic cells (DC) is the principal and primary source of IL-12p70 when blood leukocytes are stimulated with the TLR4-ligand LPS or with CD40-ligand. These so-called slanDC are characterized by the 6-sulfo LacNAc modification of PSGL-1, which is identified by the mAb M-DC8. The IL-12 response of slanDC requires a few hours of in vitro maturation, which is completely blocked in the presence of erythrocytes. This inhibition of maturation depends on the expression of CD47 on erythrocytes and of its ligand SIRPα on DC. While strictly controlled in the blood by erythrocytes, the high IL-12- and TNF-α-producing capacity of slanDC in tissues may be critical in fighting off pathogens; if uncontrolled, it may lead to adverse inflammatory reactions.
KW - CELLIMMUNO
UR - http://www.scopus.com/inward/record.url?scp=33745062776&partnerID=8YFLogxK
U2 - 10.1016/j.immuni.2006.03.020
DO - 10.1016/j.immuni.2006.03.020
M3 - Article
C2 - 16782032
AN - SCOPUS:33745062776
SN - 1074-7613
VL - 24
SP - 767
EP - 777
JO - Immunity
JF - Immunity
IS - 6
ER -